NCT07187089View on ClinicalTrials.gov

Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

85

Participants

Timeline

Start Date

November 11, 2025

Primary Completion Date

December 23, 2027

Study Completion Date

January 5, 2028

Conditions

Severe Atopic Dermatitis (AD)

Interventions

DRUG

dupilumab

Administered per the protocol

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY